Allergan Inc. (AGN): Today's Featured Drugs Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Allergan ( AGN) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day down 1.1%. By the end of trading, Allergan rose $1.97 (2.2%) to $92.30 on light volume. Throughout the day, 1,447,476 shares of Allergan exchanged hands as compared to its average daily volume of 2,816,400 shares. The stock ranged in a price between $90.57-$92.46 after having opened the day at $90.67 as compared to the previous trading day's close of $90.33. Other companies within the Drugs industry that increased today were: Gentium SpA ( GENT), up 16.6%, GW Pharmaceuticals PLC ADR ( GWPH), up 13.0%, Inovio Pharmaceuticals ( INO), up 10.4% and Alcobra ( ADHD), up 10.4%.

Allergan, Inc. operates as a multi-specialty healthcare company primarily in the United States, Europe, Latin America, and the Asia Pacific. Allergan has a market cap of $27.0 billion and is part of the health care sector. Shares are down 1.5% year to date as of the close of trading on Wednesday. Currently there are 10 analysts that rate Allergan a buy, no analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Allergan as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, impressive record of earnings per share growth and increase in stock price during the past year. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the negative front, Opexa Therapeutics ( OPXA), down 51.7%, Mast Therapeutics ( MSTX), down 40.9%, XOMA ( XOMA), down 21.3% and BioScrip ( BIOS), down 18.5% , were all laggards within the drugs industry with ACADIA Pharmaceuticals ( ACAD) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers